BDX vs SABSW · P/E 34, rev $21.84B vs P/E 0.0
Becton Dickinson and Company (BDX) versus SAB Biotherapeutics Inc (SABSW) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
SAB Biotherapeutics Inc (SABSW) common stock listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
SABSW does not have a complete income-statement cache yet.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. SABSW currently screens at market cap $0 and trailing P/E 0.0.
Not investment advice. Open the BDX and SABSW stock pages for the full models.
Not investment advice.